SURMOUNT-1: tirzepatide for weight loss
The pivotal phase 3 trial that established tirzepatide as the most effective FDA-approved weight-management medication to date — 22.5% mean weight loss at the 15 mg dose over 72 weeks.
What the trial tested
SURMOUNT-1 (Jastreboff AM, et al., New England Journal of Medicine, 2022; PMID 35658024) randomized 2,539 adults with obesity, or overweight with a weight-related complication and without diabetes, to once-weekly subcutaneous tirzepatide (5, 10, or 15 mg) or placebo, alongside lifestyle intervention, for 72 weeks.
Key results
A large majority of participants on the 10 mg and 15 mg doses achieved at least 5% weight loss, and substantial proportions reached 20% or more. The most common adverse events were gastrointestinal (nausea, diarrhea, constipation), mostly mild-to-moderate and concentrated during dose escalation.
Why it matters
The 22.5% figure is the highest mean weight loss reported in a pivotal trial for any approved weight-management medication, exceeding semaglutide's 14.9% in STEP-1 (cross-trial, not head-to-head). The result reflects tirzepatide's dual mechanism — see our journal index and the mechanism explainer.
Important caveats
- These are FDA-approved-product trial results; compounded tirzepatide is not FDA-approved and was not the product studied.
- Trial outcomes are averages; individual results vary and are not guaranteed.
- Weight regain is common after stopping; maintenance is an active area of study.
What SURMOUNT-1 actually showed
SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) randomized roughly 2,539 adults with obesity — or overweight with a weight-related complication — and without diabetes to weekly tirzepatide (5, 10 or 15 mg) or placebo for 72 weeks, alongside lifestyle counseling. Mean weight reduction was approximately 15% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, versus about 3.1% with placebo. A large majority of treated participants achieved at least 5% weight loss, and substantial proportions reached 15% and even 20% or more — thresholds rarely seen with earlier medications. These results established tirzepatide as among the most effective pharmacological weight-loss therapies studied to that point.
Secondary cardiometabolic outcomes
The trial measured more than weight. Treated participants saw improvements in waist circumference, blood pressure, fasting insulin and lipid measures, and a high proportion of those with prediabetes at baseline reverted to normal glucose regulation during the study. These secondary findings matter because they connect weight loss to the cardiometabolic risk factors that drive long-term disease — and they set up later, dedicated trials in heart failure, sleep apnea and liver disease. As always, improving risk markers is encouraging but distinct from proving reductions in events, which dedicated outcome trials address.
Strengths, limits and what it means for you
SURMOUNT-1 was large, randomized and placebo-controlled — strong evidence. But trial averages mask wide individual variation, participants were supported and monitored in ways that may exceed typical use, and the study ran 72 weeks, leaving longer-term questions to other trials such as SURMOUNT-4, which showed regain after stopping. The trial also studied the branded product; compounded tirzepatide is not FDA-approved and was not the subject of this research, so its results should not be assumed to transfer. The practical takeaway is that tirzepatide can produce large average weight loss in people with obesity, that the effect depends on continued treatment, and that any individual's results and suitability are clinical questions — not guarantees from a headline percentage.